References
- Mimori T, Harigai M, Atsumi T, Fujii T, Kuwana M, Matsuno H, et al. Safety and effectiveness of 24-week treatment with Iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan. Mod Rheumatol 2017;27:755–65.
- Tanaka K. Iguratimod (T-614): a novel disease modifying anti-rheumatic drug. Rheumatol Rep 2009;1:e4.
- Tanaka K, Kawasaki H, Kurata K, Aikawa Y, Tsukamoto Y, Inaba T. T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts. Jpn J Pharmacol 1995;67:305–14.
- Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol 2016;68:282–98.
- Ying-Ying Q, Yu T, Jin-Bing R, Jing L. Clinical observation on treatment of refractory ankylosing spondylitis by Iguratimod. J Jiangsu Univ (Med Ed) 2016;26:235–9.
- Zeng HQ, Kong WH, Peng Z, Dong HJ, Yin ZH, Chen XP, et al. Clinical observation of Iguratimod treat ankylosing spondylitis. Hainan Med J 2016;118–20.
- Machado P, Landewe R, Lie E, Kvien TK, Braun J, Baker D, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2010;7:47–53.
- Wei Y, Sun X, Hua M, Tan W, Wang F, Zhang M. Inhibitory effect of a novel antirheumatic drug T-614 on the IL-6-induced RANKL/OPG, IL-17, and MMP-3 expression in synovial fibroblasts from rheumatoid arthritis patients. Biomed Res Int 2015;2015:1–8.
- Garcia AJ, Tom C, Guemes M, Polanco G, Mayorga ME, Wend K, et al. ERα signaling regulates MMP3 expression to induce FasL cleavage and osteoclast apoptosis. J Bone Miner Res 2013;28:283–90.
- Tanaka K, Yamamoto T, Aikawa Y, Kizawa K, Muramoto K, Matsuno H, et al. Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin produced by cultured B cells and rheumatoid synovial tissues engrafted into SICD mice. Rheumatology (Oxford) 2003;42:1365–71.